Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Significant Growth in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 137,600 shares, an increase of 143.1% from the November 15th total of 56,600 shares. Based on an average daily volume of 51,400 shares, the days-to-cover ratio is currently 2.7 days.

Appili Therapeutics Stock Performance

Shares of Appili Therapeutics stock remained flat at $0.03 during trading on Wednesday. The stock had a trading volume of 77,000 shares, compared to its average volume of 156,902. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.05. The business has a 50 day simple moving average of $0.02 and a two-hundred day simple moving average of $0.03.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.